EVENT GUIDEdownload.knect365lifesciences.com/2019/TidesEuropeGuide.pdf · Don’t forget to pick up...

EVENTGUIDE

TIDES Europe:Oligonucleotide & Peptide Therapeutics

What’s Inside...Welcome . . . . . . . . . . . . . . . . . . 3Networking Opportunites/ App Information . . . . . . . . . . . . 5Health & Safety Information . . 7Poster Presentations . . . 32-33Sponsors & Exhibitors . . . . . 12Exhibit Hall Floor Plan& Exhibitor List . . . . . . . . 18-19 CONFERENCE AGENDAConference at-a-Glance . . . . .21Tuesday . . . . . . . . . . . . . . . . 23Wednesday . . . . . . . . . . .24-25Thursday . . . . . . . . . . . . .26-27Friday . . . . . . . . . . . . . . .28-29

12-15 November 2019RAI Amsterdam Convention Centre

@TIDES365 #TIDESEUROPE 3

HIGHLIGHTS AND INFORMATION

Wednesday 13th November @ The Mountain House

18.05-19.35

NETWORKING RECEPTION

WiFiSponsored by:

WiFi Network: BACHEM Password: partner1

TAXIIf coming from Schiphol airport you can take a sprinter stopping train directly to Amsterdam RAI station, which is adjacent to the exhibition centre, about 300m walk away. The train comes frequentlly and the trip takes just over 10

minutes- RAI is the second stop from Schiphol just after Amsterdam Zuid station. Check the overhead boards at Schiphol station to ensure your train stops at Amsterdam RAI. There are also taxis outside the RAI Congress Centre.

Visit our helpdesk in the Exhibition Hall Meeting Area for any queries and log in to view your schedule.

INFORMATIONIf you have any queries throughout the event please visit the registration desk and speak to a member of KNect365 staff.

For sponsorship opportunities at Tides Europe 2020, please visit the Sales Office at the back of the Exhibition Hall.

SECURITY AND BADGE SCANNINGWe may ask to scan your badge for security and monitoring purposes. Please note that when scanned by an exhibitor, the bar code on your badge allows the exhibitor to collect your contact details which they will use to

contact you for the purposes of event follow-up and to send you marketing information about their products and services.If you do not wish to share your contact information with the exhibitor for these purposes, please do not give the exhibitor permission to scan your badge.

PERSONAL BELONGINGSPlease keep your valuables and working material with you at all times. We would advise you to keep your notes with you as these cannot be replaced if lost. We regret that neither KNect365 Life Sciences nor the venue can be held responsible for any loss or damage to your property.

BEER Don't forget to pick up your free beer from lunchtime onwards at emp Biotech, stand 48

HOW TO ACCESS SPEAKER PRESENTATION SLIDESPlease go to the TIDES Europe website at https://lifesciences .knect365 .com/tides-europe/presentations to download the speaker presentations. These will be available from Tuesday 19th November. * Please note that not all speakers have consented to sharing their presentations, therefore those with an asterisk will not be shared post-event.


HEALTH & SAFETY

HEAL

TH &

SAFE

TYThe fire alarm sound in this building is a siren

If you discover a fire raise the alarm by breaking the glass at the nearest call point

Do not stop to collect your belongings or use lifts

Do not obstruct any exits or gangways

There is a no smoking policy at this event. Smoking will only be allowed outside of the venue in designated areas

Please make yourself aware of the emergency exits in your immediate area

The assembly point for this event is located in the RAI square, outside the main entrance to the Elicium, Entrance D

Should you require special assistance please tell a member of KNect365 staff

Please be responsible when plugging laptop and mobile chargers into sockets

Data ProtectionDue to increased data protection legislation, we are now unable to distribute the contact details for the speakers and delegates attending our events. Should you wish to contact anyone who has attended today's event, please log into the PartneringOne App (details on page 5) or contact a member of staff at the registration desk. and we will be happy to pass on your details to the person you would like to contact.

Liability for lost or stolen itemsKNect365 will not accept any liability for loss, theft, damage or delay resulting from the loss or theft of any item of property belonging to participants or authors or third party, and the authors and participants and third party agree that it is their responsibility to have in place adequate insurance to cover all such eventualities.

Notwithstanding the provisions of the above paragraph, in the event that such items are taken into the custody of Informa or its representatives, Informa will exercise reasonable care but its liability for any such item for loss, theft, damage or delay whilst in the care of Informa or its representatives will not exceed the value of any item or £1,000, whichever is the lower.

KNect365 may make a reasonable charge for the return of lost or unclaimed property to the participant or author or third party depending upon:

1. the type of article; and

2. the period during which Informa has held the article before it is claimed.

DisclaimerAlthough the content of conference materials is believed to be accurate, neither KNect365 nor its presenters make any representations or warranties regarding such content or materials. Please note that:- (a) anybody using or relying upon information or opinions set out in the conference materials, does so at their own risk; (b) Informa and its presenters strongly advise that independent professional judgment be exercised and/or independent professional advice should be sought before using or relying upon such information or opinions; and (c) some of the views and opinions expressed by presenters may be their own and may not necessarily represent the views or opinions of the companies or organisations by whom they are engaged or employed.by whom they are engaged or employed.

12 @TIDES365 #TIDESEUROPE

THANK YOU TO OUR SPONSORS AND EXHIBITORS

ASSOCIATE SPONSORS

SPONSORS

REGISTRATION AREA SPONSOR BEER SPONSOR

EXHIBITORS

MEDIA PARTNERS

PROMOTIONAL PARTICIPANT


EXHIBIT HALL FLOOR PLAN & EXHIBITOR LIST

116

31

2934

35

36

37 2627

3332

42

41

4045

4647 3839

44

43

52

51

50

49

48

17

18

14

13

2

6

7

8923

21

19 12

1011

25 24

4

MEETING AREA

PartneringONE help Desk & Meetings

Don’t forget to pick up your free beer from lunch onwards at emp Biotech

Posters

Agilent Technologies 16AJI Bio-Pharma Services 17Aldevron 49Almac 19Asahi Kasei Bioprocess Deutschland GmbH

47

Bachem AG 1BCN Peptides 46BianoGMP GmbH 38BioSpring 21Cambrex 44ChemGenes 14Corden Pharma International GmbH 18CS Bio 51DuPont Water Solutions 25

emp Biotech GmbH 48Innovassynth Technologies 11Intertek 27Jiangsu Hanbon Science and Technology

36

Kinovate Life Sciences 37LGC AXOLABS 6Neuland Labs 34Nitto Denko Avecia 2Peptide Scientific 24Polymun Scientific 12PolyPeptide Group 35Precision NanoSystems 32Quality Assistance 13RIBOBIO CO., LTD. 33

Sciex 39Senn Chemicals 29Sierra 9ST Pharm 23Swiss Innotech AG 10Syngene International 45Thermo Fisher Scientific 50TriLink BioTechnologies 31USV Private Ltd. 40Gore & Associates 42WuXi AppTec 52Wyatt Technologies 41YMC Process Technologies 43Zeochem AG 4

Exhibitor Stand No. Exhibitor Stand No. Exhibitor Stand No.

Exhibitors by name


116

31

2934

35

36

37 2627

3332

42

41

4045

4647 3839

44

43

52

51

50

49

48

17

18

14

13

2

6

7

8923

21

19 12

1011

25 24

4

MEETING AREA

KNect365 Sales Office

Bachem AG 1Nitto Denko Avecia 2Zeochem AG 4LGC AXOLABS 6Sierra 9Swiss Innotech AG 10Innovassynth Technologies 11Polymun Scientific 12Quality Assistance 13ChemGenes 14Agilent Technologies 16AJI Bio-Pharma Services 17Corden Pharma International GmbH 18Almac 19BioSpring 21

ST Pharm 23Peptide Scientific 24DuPont Water Solutions 25Intertek 27Senn Chemicals 29TriLink BioTechnologies 31Precision NanoSystems 32RIBOBIO CO., LTD. 33Neuland Labs 34PolyPeptide Group 35Jiangsu Hanbon Science and Technology

36

Kinovate Life Sciences 37BianoGMP GmbH 38Sciex 39

USV Private Ltd. 40Wyatt Technologies 41Gore & Associates 42YMC Process Technologies 43Cambrex 44Syngene International 45BCN Peptides 46Asahi Kasei Bioprocess Deutschland GmbH

47

emp Biotech GmbH 48Aldevron 49Thermo Fisher Scientific 50CS Bio 51WuXi AppTec 52

Exhibitor Stand No. Exhibitor Stand No. Exhibitor Stand No.

Exhibitors by stand number

PlenaryRoom

More Posters this way


CONFERENCE AT-A-GLANCE

TUESDAY 12 NOVEMBER 2019 • PRE-CONFERENCE WORKSHOPS08:00-12:00 Workshop #1: Managing CMC Activities to Accelerate Oligonucleotide

Development and Manufacturing (Room D201 - 202)Workshop #2: Analytical Strategies and Technologies for Peptide

Therapeutics (Room D203)

13:00-17:00 Workshop #3: Drug Product Development Strategies for

Oligonucleotides and Peptides (Room D201 – 202)Workshop #4: Accelerating Oligonucleotide and Peptide Drug

Development (Room D203)

WEDNESDAY 13 NOVEMBER 2019 Exhibit Hall & Poster Viewing Hours: 07:30-17:3007:30-08:05 Exhibit Viewing and Coffee in Poster and Exhibit Hall

08:10-11:55

Plenary Session: (Elicium) Anastasia Khvorova, Ph.D., Professor, RNA Therapeutics Institute, University of Massachusetts Medical School, USATakanori Yokota, M.D., Ph.D., Professor, Neurology & Neurological Science, Tokyo Medical and Dental University, Japan Fernando Albericio, Ph.D., Research Professor, Universities of Barcelona and KwaZulu-Natal, Spain and South Africa Orn Almarsson, Ph.D., Head of Formulations, Moderna Therapeutics, USA Enrico Mastrobattista, Ph.D., Professor of Pharmaceutical Biotechnology and Delivery, Utrecht University, The Netherlands Sotirios Tsimikas, M.D., Vice President of Global Cardiovascular Development, Ionis Pharmaceuticals, USA

12:00-12:30 Spotlight Presentations Sponsored by: Polymun Scientific GmbH (Elicium), Zeochem (Room D201-202), Intertek (Room D203), WL Gore (Room D204)

12:30-13:50 Networking Luncheon in Poster and Exhibit Hall

Oligonucleotide Discovery, Preclinical and Clinical

Oligonucleotide Chemistry, Manufacturing and Controls

Peptide Discovery, Preclinical and Clinical

Peptide Chemistry, Manufacturing and Controls

13:50-17:00 Novel Oligonucleotide Chemistries

and Machine Learning Guided Design (D201-202)

Analytical Control Strategies for Oligonucleotides (Elicium)

Peptide Discovery Strategies (D203)

Innovation in Peptide Manufacturing: Upstream and Downstream Processes (D204)

18:00 Attendee Networking Reception Event at The Mountain House

THURSDAY 14 NOVEMBER 2019 Exhibit Hall & Poster Viewing Hours: 08:00-16:30 08:00-

8:40 Exhibit Viewing and Coffee in Poster and Exhibit Hall08:40-10:15 Plenary Morning Keynote Session: (Elicium)

David Craik, Ph.D., Professor of Biomolecular Structure, Institute for Molecular Bioscience, University of Queensland, Australia Ralf Wagner, Ph.D., Head Section Viral Vaccines, Paul-Ehrlich-Institut, Germany

10:55-12:25 Regulatory Strategies for Oligonucleotides and Peptides (Elicium)

12:30-13:00 Spotlight Presentations Sponsored by: Ajinomoto Co., Inc. (Elicium), BioSpring (Room D201-202), Precison Nanosystems (Room D204),

Belyntic (Room D203)), Exicure (Room D203)13:00 Networking Luncheon in Poster and Exhibit Hall

Oligonucleotide Discovery,

Preclinical and Clinical

Oligonucleotide Chemistry,

Manufacturing and Controls

Peptide Discovery, Preclinical

and Clinical

Peptide Chemistry, Manufacturing

and Controls

mRNA Therapeutics and CRISPR Therapeutics

14:25-16:00 Non-Hepatic Delivery of Oligonucleotides and Other

Delivery Strategies (Elicium)

Peptide Discovery Strategies

(Room D204)

CMC Strategies for Peptides

(Room D201 - 202)mRNA Therapeutics: From

Discovery to Manufacturing and Regulatory

(Room D203)16:30-18:30 Novel Discovery Platforms

(Room D204)

CMC Strategies for Oligonucleotides

(Elicium)

Cost Efficient Production of Peptides Sponsored by Zeochem (Room D201-202)

FRIDAY 15 NOVEMBER 201908:15-08:45 Breakfast Spotlight Presentation Sponsored by: Sciex (Room D201-202)






and Clinical


and Controls


08:55-12:00 Clinical Updates on

Oligonucleotides in Development (Room D203)

Getting Ready for One-mole Scale Commercial

Manufacturing (Room D201-202)

Personalized Cancer Therapies (Room D204)

Delivery of Macromolecules (Room D204)

12:05-12:35 Spotlight Presentation Sponsored by: Wyatt (Room D201-202)

12:35-13:40 Networking Luncheon (Elicium Mezzanine)

13:40-15:15 Phase 3 Oligonucleotide Program Updates

(Room D201-202) Novel Tools and Test Methods for Peptides (Room D204) CRISPR Therapeutics and Delivery (Room D203)


TUESDAY 12 NOVEMBER 2019 • PRE-CONFERENCE WORKSHOPSDownload speaker presentations from https://lifesciences.knect365.com/tides-europe/presentations

MORNING HALF-DAY WORKSHOPS • 08:00-12:00 Workshop #1:

Managing CMC Activities to Accelerate Oligonucleotide Development and Manufacturing

Workshop #2: Analytical Strategies and Technologies for Peptide Therapeutics

Room D201-202 Room D20308:00 Workshop Moderator’s Opening Remarks

Thomas Rupp, Owner and Principal, Thomas Rupp Consulting AG, GermanyWorkshop Moderator’s Opening RemarksViv Lindo, Associate Director, Analytical Sciences, AstraZeneca

08:15 Technologies and CMC Challenges in the Manufacturing of OligonucleotidesThomas Rupp, Owner and Principal, Thomas Rupp Consulting AG, Germany

Analytical Characterization Tools for Peptide Therapeutics Physical Stability Ana Gomes dos Santos, Ph.D, Principal Formulation Scientist, AstraZeneca, United Kingdom

(8:50) Development and Validation of a Peptide BioassayMichael Postlethwaite, Ph.D., Business Development Manager, Bachem AG, Switzerland

09:15 CMC and Regulatory Experiences through Development of the Oligonucleotide CobitolimodChristine Dieterich Johansson, Ph.D., Senior Project Manager CMC and Pre-clinical, InDex Pharmaceuticals, Sweden

(09:25) Understanding the 3-D structures of a Peptide to Determine the Control Strategy for Biological ActivityMark Drew, Business Programme Lead, AstraZeneca, United Kingdom

10:00 Networking Refreshment Break10:15 (10:30) Accelerating Early Phase Development of Oligonucleotides

Kris Ruanjaikaen, Ph.D., Senior Engineer, ASO Process Development and Manufacturing, Biogen

(10:30) Peptide Oligomers – Friends or Enemies?Lise Giehm, Ph.D., Principal Scientist, Pharmaceutical Development, Zealand Pharma A/S, Denmark

10:45 (11:05) Automated Approaches to Peptide Preformulation and BiophysicsJesper Søndergaard Marino, Ph.D., Principal Scientist, Novo Nordisk A/S, Denmark

11:15 Panel Discussion with Workshop Speakers (11:40) Concluding Remarks and Discussion12:00 Networking Luncheon for Workshop Attendees

AFTERNOON HALF-DAY WORKSHOPS • 13:00-17:00 Workshop #3: Drug Product Development Strategies

for Oligonucleotides and Peptides Workshop #4: Accelerating Oligonucleotide and

Peptide Drug Development Room D201-202 Room D203

13:00 Workshop Moderator’s Opening RemarksStefan Vonhoff, Ph.D., Vice President CMC, NOXXON Pharma AG, Germany

Workshop Moderator’s Opening RemarksMimoun Ayoub, Ph.D., Director and Head of North American and Emerging Markets, CordenPharma International, Switzerland

13:15 Optimization of Novel Polymeric Delivery Vehicles by Chemical EvolutionErnst Wagner, Ph.D., Chair, Professor and Chair, Pharmaceutical Biotechnology, Department of Pharmacy, Ludwig Maximilians University, Germany

Stage Appropriate CMC Overview and Requirements for a Robust DossierMimoun Ayoub, Ph.D., Director and Head of North American and Emerging Markets, CordenPharma International, Switzerland

13:45 Investigations into Disruptive Delivery Approaches for LNA Antisense Oligonucleotides (ASO LNA)Michael Keller, Ph.D., Senior Principal Scientist, pRED, pCMC, Roche, Switzerland

(13:55) CMC Technical and Regulatory Strategies for Development of Peptides and OligonucleotidesGary F. Musso, Ph.D., President, Musso and Associates LLC, USA

14:15 Oligonucleotide Drug Product (Development) for (Ultra) Orphan Ophthalmic Diseases*Vera Brinks, Ph.D., Director, Pharmaceutics, ProQR Therapeutics, The Netherlands

14:45 Networking Refreshment Break (14:35) Networking Refreshment Break15:15 Drug Product Strategies for Peptides

Dhananjay Jere, Ph.D., Senior Principal Scientist - Principal Group Leader, Drug Product Services, Lonza AG, Switzerland

(15:10) Scale-up Peptide Manufacturing Case Study: Transition from Solid-phase to Liquid Phase SynthesisBruce Morimoto, Ph.D., Vice President, Drug Development, Cerecin, USA

15:45 Formulation Development and Device Options for the Subcutaneous Injection of Spiegelmer Drug Product SolutionStefan Vonhoff, Ph.D., Vice President CMC, NOXXON Pharma AG, Germany

(15:50) Drug Product Development and Industrialization for Peptides and Oligos: A CDMO PerspectiveUmberto Romeo, R&D Manager, Corden Pharma, Italy

16:15 Formulation and Process Parameter Development for the Terminal Sterilization of Antisense Oligonucleotide Drug ProductsLani Hack, Engineer II, ASO Formulation Development and Manufacturing, Biogen

(16:30) Closing Remarks and Discussion

16:45 Concluding Remarks and Discussion17:00 Close of Workshops

*Please note presentations marked with an asterisk will not be available post-event.


WEDNESDAY 13 NOVEMBER 2019 • MAIN CONFERENCE PLENARY Download speaker presentations from https://lifesciences.knect365.com/tides-europe/presentations

07:30 Exhibit Viewing and Coffee in Poster and Exhibit Hall

PLENARY SESSION

Elicium

08:05 Chairperson’s Remarks Bob Brown, Ph.D., CSO and SVP, Research, Dicerna Pharmaceuticals

08:10 Opening the Central Nervous System for RNAi-based Modulation

Anastasia Khvorova, Ph.D., Professor, RNA Therapeutics Institute, University of Massachusetts Medical School, USA

08:40 Systemically Administered DNA/RNA Heteroduplex Oligonucleotides That Can Efficiently Regulate CNS Genes*

Takanori Yokota, M.D., Ph.D., Professor, Neurology & Neurological Science, Tokyo Medical and Dental University, Japan

09:10 Linkers for Peptide Conjugation Fernando Albericio, Ph.D.,

Research Professor, Universities of Barcelona and KwaZulu-Natal, Spain and South Africa

09:40 Networking Refreshment Break

10:25 mRNA Vaccines and Therapeutics: From Promise to Reality

Orn Almarsson, Ph.D., Head of Formulations, Moderna Therapeutics, USA

10:55 Development of Delivery Systems for Biopharmaceuticals within the IMI COMPACT Consortium: Results and Lessons Learned

Enrico Mastrobattista, Ph.D., Professor of Pharmaceutical Biotechnology and Delivery, Utrecht University, The Netherlands

11:25 Antisense for a Billion People: The Development of RNA-based Therapy for Elevated Lipoprotein(a)

Sotirios Tsimikas, M.D., Vice President of Global Cardiovascular Development, Ionis Pharmaceuticals, USA

11:55 Transition to Spotlight Presentation Rooms

12:00-12:30

CONCURRENT SPONSORED SPOTLIGHT PRESENTATIONS

: (Elicium)

Guiding RNA Formulations from Laboratory into Clinical Trials. Lessons Learned from Development and Optimization of Liposomal FormulationsAndreas Wagner, Ph.D., Head of Liposome Technology, Polymun Scientific GmbH, Austria

(Room D201-202)

ZEOsphere DRP Mixed-Mode for Oligonucleotide PurificationVictoria Custodis, Ph.D., Team Leader R&D, Zeochem AG, Switzerland

(Room D203)

Improved Separation and Maximised Throughput of a LC-MS Method for Therapeutic Oligonucleotides Magdalena Kiezel-Tsugunova, Ph.D., Project Manager, Intertek Pharmaceutical Services, United Kingdom

(Room D204)

A Single-Use Solution to Bulk Tray Lyophilization of Polypeptide and Oligonucleotide TherapeuticsScott Ross, Global Product Specialist, W. L. Gore & Associates

12:30 Networking Luncheon in Poster and Exhibit Hall



WEDNESDAY 13 NOVEMBER 2019 • MAIN CONFERENCE Download speaker presentations from https://lifesciences.knect365.com/tides-europe/presentations





and ControlsNovel Oligonucleotide

Chemistries and Machine Learning Guided Design

Analytical Control Strategies for Oligonucleotides Peptide Discovery Strategies

Innovation in Peptide Manufacturing: Upstream and

Downstream Processes

Room D201-202 Elicium Room D203 Room D20413:50 Chairman’s Remarks

Troels Koch, Ph.D., Industry Expert, Denmark

Chairman’s RemarksNadim Akhtar, Ph.D., Principal Scientist Characterization & Control Strategy, Pharmaceutical Technology and Development, AstraZeneca Macclesfield, United Kingdom

Chairman’s RemarksRami Hannoush, Ph.D., Principal Scientist & Group Leader, Early Discovery Biochemistry, Genentech, USA

Chairman’s RemarksNeil Thompson, Group Commercial Director, PolyPeptide Group, Sweden

14:00 Machine Learning-guided Design of Antisense OligonucleotidesPeter Hagedorn, Ph.D., Senior Principal Scientist and Group Leader, Roche Pharma Research and Early Development, Roche Innovation Center Copenhagen A/S, Denmark

Characterization of Raw Materials for the Manufacturing of OligonucleotidesHüseyin Aygün, Ph.D., Chief Scientific Officer, BioSpring GmbH, Germany

Early Implementation of Appropriate Studies to Identify Preclinical Liabilities is Key to Success in Peptide Drug Discovery*Federica Orvieto, Senior Research Investigator, Peptide Chemistry, IRBM Science Park SPA, Italy

Gly-His Tag Acylation for N-terminal Chemical Modification of ProteinsKnud Jørgen Jensen, Ph.D., Professor, Department of Chemistry, University of Copenhagen, Denmark

14:30 Novel Chemistries for RNAi Therapeutics Muthiah (Mano) Manoharan, Ph.D., Senior Vice President of Drug Discovery, Alnylam Pharmaceuticals, USA

Purge-based Risk Assessment for Solvent and Small Molecule Impurities Generated during Oligonucleotide ManufactureBen Andrews, Ph.D., Scientific nvestigator, GlaxoSmithKline, United Kingdom

Developability and Preformulation of PeptidesJette Boll, Ph.D., Senior Research Scientist, Ferring Pharmaceuticals, Denmark

Improving Peptide Manufacturing and Process Performance*Olivier Ludemann-Hombourger, Ph.D., Director, Global Innovation and Technology, PolyPeptide Group, France

15:00 Gap Modifications Improve Therapeutic Index of Gapmer ASOsMichael Oestergaard, Ph.D., Research Fellow, Ionis Pharmaceuticals, USA

Deeper Understanding of Separation of Native and Phosphorothioated Oligonucleotides and Their Impurities Using Ion-pair Reversed Phase ChromatographyMartin Enmark, Ph.D., Researcher, Karlstad University, Sweden

Emerging Approaches in Peptide Drug Discovery and Their Applications in Targeting Protein-Protein InteractionsRami Hannoush, Ph.D., Principal Scientist & Group Leader, Early Discovery Biochemistry, Genentech, USA

Ultra-fast Development and Optimization of Large-Scale Peptide Manufacturing ProcessesJens Bukrinski, Ph.D., Head of R&D, SB3000 Ltd., Denmark

15:30 Networking Refreshment Break in Poster and Exhibit Hall16:00 Introduction of Non-chiral

Phosphorodithioates into Locked Nucleic AcidsMeiling Li, Ph.D., Scientist, Hoffmann-La Roche, Switzerland

Strategies for Identity Testing of Oligonucleotide Therapeutics Nadim Akhtar, Ph.D., Principal Scientist Characterization & Control Strategy, Pharmaceutical Technology and Development, AstraZeneca Macclesfield, United Kingdom

Development of the Stable, Fast Acting Glucagon Analogue NN9513 for Clinical TestingJesper F. Lau, Ph.D., Scientific Director, Research Chemistry, Novo Nordisk A/S, Denmark

Development of New Multicolumn Processes and the Presentation of a New Concept with a Single ColumnJosé Paulo Mota, Ph.D., Professor, Chemical & Biochemical Engineering, Universidade NOVA de Lisboa, Portugal

16:30 Control of Backbone Stereochemistry Provides a New Dimension for the Optimization of Oligonucleotide Drug Candidates Chandra Vargeese, Ph.D., SVP, Head of Drug Discovery, WAVE Life Sciences, USA

Phase Appropriate Method Validation Strategies for Antisense Oligonucleotides with Accelerated Product Development Timelines*Stacey Traviglia, Ph.D., Associate Director, Quality Control Analytical Technology, Biogen, USA

Outer Membrane Targeting Antibiotics (OMPTA): Preclinical and Clinical Development of a Novel Class of Antibiotics against Life-threatening Gram-negative Infections*Anatol Luther, Ph.D., Head of Chemistry, Polyphor Ltd., Switzerland

Continuous Chromatography of Synthetic Peptides Ralf Eisenhuth, Ph.D., Scientific Expert API Production, Bachem AG, Switzerland

17:00 Secarna’s LNAplusTM ASOs for Treatment of Cancer and Kidney DiseaseFrank Jaschinski, Ph.D., Chief Scientific Officer, Secarna Pharmaceuticals, Germany

Trends in Developing Oligo-specific CMC Understanding by Exploiting Prior KnowledgeNigel Richardson, Ph.D., Senior Director CMC Analytical, Product Development & Supply, MST, R&D, GlaxoSmithKline, United Kingdom

Development of Novel Peptide Therapeutics*Efrat Halbfinger, Ph.D., Senior Director of Chemistry, BioLineRx, Israel

Panel Discussion with Session SpeakersPanel Moderator: Neil Thompson, Group Commercial Director, PolyPeptide Group, Sweden

17:30 Close of Sessions18:00 Attendee Networking Reception Event at The Mountain House



THURSDAY 14 NOVEMBER 2019 • PLENARY KEYNOTE Download speaker presentations from https://lifesciences.knect365.com/tides-europe/presentations

PLENARY SESSION

Elicium 08:00 Exhibit Viewing and Coffee in Poster and Exhibit Hall

08:40 Chairperson’s Remarks Jessica Stolee, Ph.D., Associate Director, Pharma and ASO Analytical Development, Biogen

08:45 Plants as Biofactories for Producing Peptide-based Pharmaceuticals

David Craik, Ph.D., Professor of Biomolecular Structure, Institute for Molecular Bioscience, University of Queensland, Australia

9:30 Regulatory Quality and CMC Perspectives on mRNA Vaccines and Peptide Vaccine Adjuvants

Ralf Wagner, Ph.D., Head Section Viral Vaccines, Paul-Ehrlich-Institut, Germany

10:15 Networking Refreshment Break in Poster & Exhibit Hall

REGULATORY STRATEGIES FOR OLIGONUCLEOTIDES AND PEPTIDES

10:55 A Case Study of Concurrent Global Regulatory Filings for Two Oligonucleotides

Jennifer Franklin, Director, CMC Regulatory Affairs, Ionis Pharmaceuticals, USA

11:25 Experience with Early and Late Phase Global Submissions of Oligonucleotide-based Products

Cinzia Gazziola, Ph.D., Technical Regulatory Affairs Manager, Hoffmann-La Roche, Switzerland

11:55 Peptide Regulatory Perspectives and Expectations

Peter Larsson, Global Director, Regulatory Affairs, PolyPeptide Group, Sweden


12:30-13:00

CONCURRENT SPONSORED SPOTLIGHT PRESENTATIONS

(Elicium)

Mass-Production of Target RNA by MicroorganismShuhei Hashiro, Research Scientist, Research Institute for Bioscience Products & Fine Chemicals, Ajinomoto Co., Inc., Japan

(Room D201-202)

Quantification of Selected Impurities in OligonucleotidesJan Nickolaus, Head of Quality Control Lab, BioSpring, Germany

(Room D204)Accelerating the Development of Transformative Nanomedicines with NxGen Microfluidics TechnologySamuel Clarke, Ph.D., Director, Research and Development, Precision NanoSystems

(12:30-12:45) (Room D203)

Changing the Tide in Peptides – Peptide Purification and Modification with Belyntic’s Catch-and-Release TechnologyOliver Reimann, Ph.D., Co-Founder, Belyntic GmbH, Germany

(12:45-13:00) (Room D203)

Delivery Outside the Liver- Locally Applied Spherical Nucleic AcidsDavid Giljohann, Ph.D., CEO, Exicure, USA

13:00 Networking Luncheon in Poster and Exhibit Hall


THURSDAY 14 NOVEMBER 2019 • MAIN CONFERENCE Download speaker presentations from https://lifesciences.knect365.com/tides-europe/presentations






Non-Hepatic Delivery of Oligonucleotides and Other Delivery Strategies

Peptide Discovery Strategies

CMC Strategies for Peptides

mRNA Therapeutics: From Discovery to Manufacturing

and RegulatoryElicium Room D204 Room D201-202 Room D203

14:25 Co-Chairpersons’ RemarksMuthiah (Mano) Manoharan, Ph.D., Senior Vice President of Drug Discovery, Alnylam Pharmaceuticals, USA

Chairperson’s RemarksBruce Morimoto, Ph.D., Vice President, Drug Development, Cerecin, USA

Chairperson’s RemarksAnnie De Groot, M.D., Professor (Research) and Director, Institute for Immunology and Informatics, University of Rhode Island and Founder, CEO and CSO, Epivax, Inc., USA

Chairperson’s RemarksAnthony Partridge, Ph.D., Senior Principal Scientist, Early, Discovery Pharmacology, Translational Medicine Research, Centre, Merck Sharp & Dohme, Singapore

14:30 Overcoming Extra- and Intracellular Barriers: Polymer-based mRNA Delivery Systems*Joanna Rejman , Ph.D., Associate Director Neurologic and Pulmonary Diseases, Product Design & Formulation, CureVac AG, Germany

Therapeutic Peptide Review and Emerging Peptide Science*Michael Dunn, Ph.D., Senior Director, Scientific Information & Intelligence, Ferring Research Institute, USA

Short Oral Poster PresentationsSee p. 32-33 for poster titles: Poster D2 - Gabriela Ivanova-Berndt, Ph.D., Senior Scientist, Bicycle Therapeutics, United KingdomPoster D5 - Thomas Bruckdorfer, Ph.D., CSO & VP Business Development, Iris Biotech GmbH, GermanyPoster D1 - Ivo Eggen, Section Lead DTS Development & External Relocations, Aspen Oss, The Netherlands

Inhibition and Degradation of Drug Targets Using bioPROTAC mRNAs – A Novel Approach with Broad Therapeutic Potential*Anthony Partridge, Ph.D., Senior Principal Scientist, Early Discovery Pharmacology, Translational Medicine Research Centre, Merck Sharp & Dohme, Singapore

15:00 Progress in Extrahepatic Silencing with siRNA ConjugatesKirk Brown, Ph.D., Director, CNS Early Development, Alnylam Pharmaceuticals

Biopharmaceutical Properties of Peptide: polyethylene Glycol Supramolecular Assemblies*Christopher van der Walle, Ph.D., Director, Fellow, Biopharmaceutical Development, MedImmune Ltd., United Kingdom

Development of Long Contiguous Overlapping Peptides for Ultra-Fast Allergy ImmunotherapyVanya Beltrami, Ph.D., VP, Head of Manufacturing, Anergis SA, Switzerland

TriMix Based mRNA Immunotherapies Stefaan De Koker, Ph.D., Non-clinical Principal Scientist and Site-Director Ghent, eTheRNA, Belgium

15:30 Targeted Delivery of Antisense Oligonucleotides to Extra-hepatic TissuesMichael Oestergaard, Ph.D., Research Fellow, Ionis Pharmaceuticals, USA

Engineered Amphiphilic Peptides Enable Delivery of Protein and CRISPR Cargoes to Cells*David Guay, Ph.D., Research Director, Feldan Therapeutics

Screen for Immunogenicity? What Does that Mean! An Expert’s Guide to Immunogenicity Screening for Peptide DrugsAnnie De Groot, M.D., Professor (Research) and Director, Institute for Immunology and Informatics, University of Rhode Island and Founder, CEO and CSO, Epivax, Inc., USA

Immune Modulation of mRNAAmy Rabideau, Ph.D., Senior Scientist, Drug Substance Process Development, Moderna, USA

16:00 Networking Refreshment Break in Poster and Exhibit HallRoom D204 Elicium Room D201-202 Room D203

16:30 Strategies for the Delivery of Nucleic Acid TherapeuticsJames Heyes, Ph.D., SVP, Technology Development, Genevant Sciences, USA

CMC Strategies for Oligonucleotides

Chairperson: David Tew, Project Leader and GSK Senior Fellow,

Advanced Manufacturing Technology, GlaxoSmithKline, United Kingdom

Cost Efficient Production of Peptides Sponsored by:

Session Chair: Jürgen Machielse, Business Development Director, Spherical Gels, Zeochem, Switzerland

Messenger RNA Therapeutics for Primary Ciliary Dyskinesia*Christian Plank, Ph.D., Chief Technology Officer, Ethris GmbH, GermanyGalNAc Cluster: Process

Chemistry and Regulatory Considerations* Martin Olbrich, Ph.D., Process Chemist, F Hoffmann-La Roche Ltd., Switzerland

Process Mass Intensity of Preparative HPLC Purification ProcessesRalf Eisenhuth, Ph.D., Scientific Expert API Production, Bachem AG, Switzerland

17:00 Developing an Engineered Exosome Therapeutics Platform*Sriram Sathy, Ph.D., Vice President Biology and Translational Medicine, Codiak Biosciences, USA

Challenges Associated with Evolvement of Oligonucleotides Process Technology - From a CMO’s Perspective*Sibo Jiang, Ph.D., Manager, Process Development, Nitto Denko Avecia

Chemo-enzymatic Peptide Synthesis; Peptide Chain Length Becomes Less RelevantLeendert van den Bos, Ph.D., Chief Executive Officer, EnzyTag BV, The Netherlands

Self Amplifying mRNA (SAM) Vaccines for Rapid ResponseDerek O’Hagan, Ph.D., Head of Global Discovery Support & New Technologies, GSK Vaccines, USA

17:30 Novel Discovery Platforms Complete Enzyme Catalysed Oligonucleotide Synthesis: From Single Nucleotides to Final ProductDavid Tew, Project Leader and GSK Senior Fellow, Advanced Manufacturing Technology, GlaxoSmithKline, United Kingdom

Cost Efficient Peptide & Oligonucleotide Purification via ZEOsphere DRP Mixed-Mode Chromatography Victoria Custodis, Ph.D., Team Leader R&D, Zeochem AG, Switzerland

Semi-automated Manufacturing of mRNA Nanoparticle Products for Personalized Neoantigen-specific Cancer ImmunotherapySebastian Hörner, Head of Process Development, Formulation & Drug Delivery, BioNTech AG, Germany

TANGO (Targeted Augmentation of Nuclear Gene Output) for the Treatment of Genetic Diseases Huw M. Nash, Ph.D., Chief Operating Officer & Chief Business Officer, Stoke Therapeutics, USA

18:00 MicroRNAs - An Emerging Attractive Drug Discovery Platform for Therapeutic Intervention in OncologyMichel Janicot, Ph.D., Chief Development Officer, InteRNA Technologies, The Netherlands

Analytical Considerations for Late Stage OligonucleotidesJessica Stolee, Ph.D., Associate Director, Pharma and ASO Analytical Development, Biogen

The Role of Membranes in (Pep)tide Synthesis: An Alternative Method of Addressing the Sustainability Challenges in Synthesis and PurificationDominic Ormerod, Ph.D., Project Manager, Process Intensification, VITO, Belgium

Regulatory View on mRNA Challenges in the Context of ATMP/Gene Therapy GuidelinesMargit Schnee, Ph.D., Regulatory Affairs Manager CMC, Curevac AG, Germany

18:30 Close of Day *Please note presentations marked with an asterisk will not be available post-event.


FRIDAY 15 NOVEMBER 2019 • MAIN CONFERENCE Download speaker presentations from https://lifesciences.knect365.com/tides-europe/presentations

8:15 Breakfast Spotlight Presentation (Room D201-202): Quantitation and Characterization of Oligonucleotides by CE and MSStephen Lock, Ph.D., Business Development & Marketing Manager, CE (EMEAI), SCIEX, United Kingdom






and Clinical

Peptide Chemistry, Manufacturing and

Controls

mRNA Therapeutics and CRISPR

Therapeutics

Clinical Updates on Oligonucleotides in

Development

Getting Ready for One-mole Scale

Commercial ManufacturingPersonalized Cancer Therapies

Room D203 Room D201-202 Room D2048:55 Chairman’s Remarks

David Evans, Ph.D., Chief Scientific Officer, Sirnaomics, USA

Chairman’s RemarksYogesh Sanghvi, Ph.D., President, Rasayan, USA

Chairman’s RemarksJesse Dong, Ph.D., Vice President, Peptide Chemistry, Neon Therapeutics

9:00 ApTOLL, A New Therapeutic Approach for the Treatment of Ischemic StrokeMacarena Hernández-Jiménez, Ph.D., Chief Scientific Officer, AptaTargets S.L., Spain

Considerations for Ton-scale Oligonucleotide Manufacturing via Solid-phase synthesis, Preparing for the Future* Isaiah Cedillo, Director, Manufacturing & Operations, Ionis Pharmaceuticals

Development of Personal Neoantigen Cancer Vaccine NEO-PV-01 Jesse Dong, Ph.D., Vice President, Peptide Chemistry, Neon Therapeutics

9:30 SiRNA Therapeutics for Oncology: New Avenues to SuccessDavid Evans, Ph.D., Chief Scientific Officer, Sirnaomics, USA

The Journey from Clinical Manufacturing to Commercially Validated Manufacturing in Partnership with CMOsCarl ‘Charlie’ Hitscherich, Ph.D., Global Head of External Manufacturing and Clinical Supply Chain, Alnylam Pharmaceuticals

Individualized Neoantigen-specific Therapy against Cancer Using messenger RNA*Christoph Kröner, Ph.D., Head of IVAC Mutanome Lead Structure, BioNTech AG, Germany

10:00 Inhibition of microRNA-155 as a Therapeutic Strategy for the Treatment of Hematological MalignanciesWilliam S. Marshall, Ph.D., President & CEO, miRagen Therapeutics, Inc., USA

Improving the Oligonucleotide Solid-Phase Synthesis Process to Increase the Output of Existing Equipment Xianglin Shi, Ph.D., Principal Scientist, ASO Process Development and Manufacturing, Biogen

Delivering of Novel Cure: Unbridling the Power of mRNA-based MedicinesHangwen Li M.D., Ph.D., Chairman and CEO, Stemirna Therapeutics, China

10:30 Networking Refreshment Break11:00 Clinical Development

of CXCL12 Inhibiting L-RNA Aptamer NOX-A12 (Olaptesed Pegol) Dirk Eulberg, Ph.D., Vice President Project Management, NOXXON Pharma AG, Germany

Trinucleotide Phosphoramidites: Synthons for Codon-based Gene Synthesis and Blockmers for Oligonucleotide AssemblySabine Müller, Full Professor for Biochemistry, Institute of Biochemistry, University of Greifswald, Germany

Delivery of Macromolecules Applying New Imaging Modalities to the ADME of ASO and Peptide Drugs*Steve Hood, Ph.D., Director, Bioimaging and D@T, GlaxoSmithKline, United Kingdom

11:30 The Oligonucleotide Agent BC 007 for Neutralization of Pathogenic Agonistic Autoantibodies Directed Against ß 1-Adrenoceptors in Heart Failure Patients – Up-date with Very First Phase II DataJohannes Mueller, M.D., CEO and Founder, Berlin Cures, Switzerand

Nanostar Sieving for Liquid Phase Synthesis of OligonucleotidesAndrew Livingston, Ph.D., Professor of Chemical Engineering, Imperial College London, United Kingdom

Targeted Drug Delivery to the CNS and Peripheral Tissues Using the VECTrans® Innovative TechnologyGuillaume Jacquot, Ph.D., Translational Research Manager, Vect-Horus, France




FRIDAY 15 NOVEMBER 2019 • MAIN CONFERENCE Download speaker presentations from https://lifesciences.knect365.com/tides-europe/presentations

CONCURRENT SPONSORED SPOTLIGHT PRESENTATIONS12:05

Spotlight Presentation: Peptides – What Light Scattering Can Do (Room D201-202)

Roger Scherrers, Ph.D., Head of Analytical Service, Wyatt Technology, Germany

12:35Networking Luncheon (Elicium Mezzanine)






and Clinical

Peptide Chemistry, Manufacturing and

ControlsmRNA Therapeutics and

CRISPR Therapeutics

Phase 3 Oligonucleotide Program Updates

Novel Tools and Test Methods for Peptides CRISPR Therapeutics and Delivery

Room D201-202 Room D204 Room D20313:40 Chairperson’s Remarks

John Richards, Ph.D., Senior Vice President and Head of Pharmaceutical Development, The Medicines Company

Chairperson’s RemarksDennis Åsberg, Research Scientist, Analysis & Separation, Novo Nordisk A/S, Denmark

Chairperson’s RemarksJohn Zuris, Ph.D., Scientist III, Editas Medicine, USA

13:45 Clinical Development of Tivanisiran, A siRNA for the Treatment of Dry Eye DiseaseAnne-Marie Bleau, Ph.D., Clinical Operations Manager, Sylentis, Spain

Control Strategies and Analytical Test Methods for Peptide-ConjugatesSilvan Rihm, Senior Chemist, Bachem AG, Switzerland

Strategies for Translocation Reduction during CRISPR/Cas MultiplexingJohn Zuris, Ph.D., Scientist III, Editas Medicine, USA

14:15 Breakthrough Treatment with Twice a Year Shots to Prevent Heart Attacks and Strokes: Inclisiran Is a New Class of Cholesterol Lowering DrugsJohn Richards, Ph.D., Senior Vice President and Head of Pharmaceutical Development, The Medicines Company

From Homebrewing to Peptide ChemistryJohn Lopez, Ph.D., Fellow, Chemical R&D, Novartis, Switzerland

Highly Efficient Gene Knockdown of Mouse Liver Genes Via Base Editing Using Non-viral Delivery of CRISPR-Cas9 Base Editors*Francine Gregoire, Ph.D., VP, Liver Diseases, Beam Therapeutics, USA

14:45 Phase 3 Data of Givosiran, Investigational RNAi Therapeutic for Acute Hepatic PorphyriaElisabeth Minder, M.D. , Professor and Honorary Consultant, Department of Endocrinology, Diabetology, Porphyria, Triemli City Hospital, Switzerland

Designing a Peptide Quantification Strategy for Early Drug Discovery – Ultraviolet, Refractive Index and Charged Aerosol Detection vs. Amino Acid Analysis* Dennis Åsberg, Research Scientist, Analysis & Separation, Novo Nordisk A/S, Denmark

Investigation of Lipid Nanoparticle Formulation Optimisations across Nucleic acid-based ModalitiesLili Cui, Ph.D., Senior Formulation Scientist, PharmSci, AstraZeneca, United Kingdom

15:15 Close of TIDES Europe 2019 Nanocarrier for CRISPR Gene Editing and mRNA-mediated Tumor Suppressor RescueGilles Divita, Ph.D., Chief Executive Officer, Divincell SAS, France

15:45 Close of TIDES Europe 2019



TIDES EUROPE 2019 ADVISORY BOARD


Mimoun Ayoub, Ph .D ., Director and Head of North American and Emerging Markets, CordenPharma International, Switzerland

Fabrizio Badalassi, Ph .D ., Director, Chemical Development, Ferring Pharmaceuticals, Denmark

Alastair Hay, Ph .D ., Account Manager, Peptide and Protein Technology, Almac, United Kingdom

Ewa Kowalska, Chemical Process Development Manager, API Development, Ipsen Manufacturing Ireland Ltd .

Viv Lindo, Associate Director, Analytical Sciences, AstraZeneca

Leila Malik, Ph .D ., CMC Project Manager, Zealand Pharma AS, Denmark

Thomas Meier, COO Europe, Bachem AG, Switzerland

Neil Thompson, Group Commercial Director, PolyPeptide Group, Sweden


Waleed Danho, Ph .D ., Consultant, Danho & Associates, USA

Jesse Z . Dong, Ph .D ., Vice President, Peptide Chemistry, Neon Therapeutics, USA

Jesper Lau, Ph .D ., VP, Protein and Peptide Chemistry, Global Research, Novo Nordisk A/S, Denmark

Les Miranda, Ph .D ., Executive Director Research, Structural Biology, Molecular Modeling, & Hybrid Modality Engineering, Amgen, USA

Bruce Morimoto, Ph .D ., Vice President, Drug Development, Cerecin, USA

Oligonucleotide Chemistry Manufacturing and Controls

Nadim Akhtar, Ph .D ., Principal Scientist Characterization and Control Strategies, AstraZeneca, United Kingdom

Alun Garner, Business Development Manager, Nucleic Acid Solutions Division, Agilent Technologies, Inc ., USA

Annekathrin Haberland, Ph .D ., Director, Regulatory Affairs, Berlin Cures GmbH, Germany

Rachel Orr, GSK Associate Fellow, Enablement Manager, GlaxoSmithKline R&D, United Kingdom

Thomas Rupp, Owner & Principal, Thomas Rupp Consulting, Germany

Yogesh Sanghvi, Ph .D ., President, Rasayan, USA

Jessica Stolee, Ph .D ., Associate Director, CMC, Biogen, USA

David Tew, Project Leader and GSK Senior Fellow, Advanced Manufacturing Technology, GlaxoSmithKline, United Kingdom

Sridhar Vaddeboina, Ph .D ., Vice President , Analytical Development, Technology Innovation Improvement Management, Nitto Denko Avecia Inc ., USA

Stefan Vonhoff, Ph .D ., Vice President CMC, NOXXON Pharma AG, Germany


Troels Koch, Ph .D ., Industry Expert, Denmark

Muthiah (Mano) Manoharan, Ph .D ., Senior Vice President of Drug Discovery, Alnylam Pharmaceuticals, USA

Dmitry Samarsky, Ph .D ., Chief Technology Officer, Sirnaomics, USA

Punit Seth, Ph .D ., Vice President, Medicinal Chemistry, Ionis Pharmaceuticals, USA

mRNA Therapeutics

Christoph Kröner, Ph.D., Head of IVAC Mutanome Lead Structure, BioNTech AG, Germany

Hari Pujar, Ph .D ., Vice President, Technical Development and Manufacturing, Moderna Therapeutics, USA

Joanna Rejman, Ph .D ., Associate Director Neurologic and Pulmonary Diseases, Product Design & Formulation, CureVac AG, Germany

Special thank you to our expanded TIDES Europe Advisory Board, who helped bring new content and expertise to this year’s conference agenda .


Poster Presentations

Dedicated Poster Viewing HoursEven- Numbered Posters (ending in 2,4,6)

Wednesday 13 November: 13:00-13:45

Odd-Numbered Posters (ending in 1,3,5)

Thursday 14 November: 13:30-14:15

Exhibit Hall & Poster Viewing Hours

Wednesday 13 November, 07:30-17:30Exhibit Viewing and Coffee in Poster and Exhibit Hall - 07:30-08:05AM Refreshment Break – 09.40-10.25Lunch — 12:30-13:50PM Refreshment Break – 15:30-16:00

Thursday 14 November, 08:00-16:30Exhibit Viewing and Coffee in Poster and Exhibit Hall - 08:00-8:40AM Refreshment Break – 10:15-10:55Lunch —13:00-14:25PM Refreshment Break – 16:00-16:30

Poster presentations will be on display at all times during Exhibit Hall viewing hours. Poster presenters may stand by their posters at any time, but to ensure that attendees are able to meet poster presenters at specific times during the conference, we have designated the listed days/times as “Dedicated Poster Viewing” Hours. We ask poster presenters to stand by their posters during the dedicated hours listed to make it easy for attendees to “find” you. We will be promoting these dedicated poster viewing hours during the conference to facilitate better attendee and poster presenter interactions and discussions.

OLIGONUCLEOTIDE DISCOVERY, PRECLINICAL AND CLINICALA1 Development of a bioanalysis method for oligonucleotide-peptide

conjugates using hybridisation-based sample clean up and LC-MSAnders Björkbom

AstraZeneca

A2 Identification of potent and specific antisense oligonucleotides for target gene knockdown using a high-throughput RT-qPCR based cellular screening platform

Amparo Cuéllar Biogazelle

A3 Applications of the LNA and RNAscope combined assay: Co-expression analysis of microRNA-21 and TNF-alpha mRNA in colorectal cancer

Boye Schnack Nielsen

Bioneer AS

A4 AsiDNA a first in class clinical stage Decoy Agonist targeting DNA repair pathways through a unique MoA enabled by the oligonucleotide modality

Florent Ubelmann

ONXEO

A5 Characterization of Synthetic Oligonucleotides using LC-MS and LC MS/MS

Aurélien Boland Sciex

A6 Automatic Top-Down Spectral Annotation of Modified Oligonucleotides Emma Harry Waters

OLIGONUCLEOTIDE CHEMISTRY, MANUFACTURING AND CONTROLSB1 Polymeric Adsorbents as Chromatographic Reverse Phase Media for

Peptides and OligonucleotidesSophie Corbet DuPont

B2 Compliant-ready Workflow for Mass Characterization of Oligonucleotide and Related Impurities

Christopher Knowles

Waters

B3 Automated Multi Attribute Quality Assessment of Synthetic Oligonucleotides and Peptides

Detlev Suckau Bruker Daltonics

B4 The potential of Bio-inert UHPLC columns in the development and validation of purity and assay test methods for synthetic oligonucleotides

Willy Verluyten Janssen Pharma

B5 INNOVASSYNTH- Preferred Partner for Protected Nucleosides, Amidites and GalNAc Derivatives

Vipul Rana Innovassynth Technologies

B6 Proof of concept for rapid scalable manufacturing of mRNA encoding a neutralising mAb

Martyn Hulley Astrazeneca

PEPTIDE DISCOVERY, PRECLINICAL AND CLINICALC1 Spontaneously cleavable glycosylated linkers for peptides without

suitable glycosylation sitesSofia Elouali GlyTech, Inc.

C2 Quadruplex priming amplification at range of normal human body temperature

David Gvarjaladze

Ilia State University

C3 Software assisted analysis for peptide drug metabolism Tatiana Radchenko

Lead Molecular Design S.L.


Poster Presentations

PEPTIDE CHEMISTRY, MANUFACTURING AND CONTROLSD1 GC-LPPS: Aspens Green Continuous Liquid Phase Peptide Synthesis -

GREEN, LEAN & CLEANIvo Eggen Aspen Oss

D2 Novel small molecule scaffolds for construction of bicyclic peptides (Bicycles®): Impact on secondary structure, physicochemical properties and protein binding

Gabriela Ivanova-Berndt

Bicycle Therapeutics

D3 Liquid Phase Peptide Synthesis via Nanostar-Sieving Jet Yeo Imperial College London

D4 Orthogonal Peptide Purification by Catch-and-Release Oliver Reimann Belyntic

D5 Fmoc-Cys(Msbh) - A Sophisticated Building Block for the Production of Cysteine-rich Peptides. A Journey from Discovery to Large Scale Production.

Thomas Bruckdorfer

Iris Biotech GmbH

D6 Quality by Design applied to true end-to-end continuous peptide synthesis in large scale leading to a 10 times reduction in the consumption of DMF and pipiridine as compared to batch manufacturing

Jens Bukrinski Swedish Biomimetics 3000 Ltd

D7 Breaking the yield-purity trade-off in chromatography purification of peptides and oligonucleotides

Thomas Müller-Späth

YMC Process Technologies

DELIVERY OF MACROMOLECULAR THERAPEUTICSE1 Ferritin-based DDS technology for TIDES Ippei Inoue Ajinomoto Co., Inc.

E2 To overcome the delivery problem of morpholino oligonucleotides and ThioRNA

Jayanta Kundu Indian Association for the Cultivation of Science

E3 Cell selective mRNA delivery through stabilin-dependent uptake of lipid nanoparticles

Roy Pattipeiluhu Leiden University

E4 Delivery of nucleic acids in vivo using SS-cleavable and pH-responsible lipid-like materials

Daniel Zucker NOF EUROPE GmbH

E5 Viromer Enabling Cas9 Delivery Steffen Panzner Lipocalyx

E6 Characterization of Adeno-Associated Virus (AAV) Using Capillary Electrophoresis

Steve Lock SCIEX

E7 Robust and Scalable Manufacturing of mRNA Lipid Nanoparticles Using a Novel Microfluidic Mixing Technology

Samuel Clarke Precision NanoSystems

mRNA AND CRISPR THERAPEUTICSF1 Non-viral in vivo mRNA delivery for cancer research, vaccination or

gene therapyValérie Toussaint

POLYPLUS-TRANSFECTION

F2 Considerations for the Development, Scale-up and Manufacturing of mRNA Therapeutics

Craig Dobbs TriLink BioTechnologies

F3 Exosome-LNP hybrid mediated delivery of siRNA and mRNA: A comparison of Hybridosomes and state-of-the-art LNPs

Joel de Beer Anjarium Biosciences AG

F4 mSENSTM technology as an antigen delivery platform targeting spleen for the therapeutic mRNA Cancer Vaccine

Joon Young Park

Samyang Biopharmaceuticals

F5 Considerations and constraints for Scale-up of mRNA Maiken Kristiansen

AstraZeneca


www.AsiaTIDESevent.com

24-26 February 2020Westin Miyako KyotoKyoto, Japan

THE ONLY EVENT IN ASIA BRINGING TOGETHER SCIENCE,TECHNOLOGIES AND PARTNERS TO ACCELERATEOLIGONUCLEOTIDE AND PEPTIDE MOLECULES TO MARKET

TIDES: Oligonucleotide &Peptide Therapeutics

May 11-14, 2020Hynes Convention CenterBoston, MA

THE WORLD’S LARGEST MEETING TO ACCELERATE OLIGONUCLEOTIDE AND PEPTIDE PRODUCTS FROM EARLY DISCOVERY TO LATE-STAGE DEVELOPMENT & COMMERCIALIZATION

www.TIDESevent.com


Notes_________________________________________________________________________________________________________________________________

_________________________________________________________________________________________________________________________________

_________________________________________________________________________________________________________________________________

_________________________________________________________________________________________________________________________________

_________________________________________________________________________________________________________________________________

_________________________________________________________________________________________________________________________________

_________________________________________________________________________________________________________________________________

_________________________________________________________________________________________________________________________________

_________________________________________________________________________________________________________________________________

_________________________________________________________________________________________________________________________________

_________________________________________________________________________________________________________________________________

_________________________________________________________________________________________________________________________________

_________________________________________________________________________________________________________________________________

_________________________________________________________________________________________________________________________________

_________________________________________________________________________________________________________________________________

_________________________________________________________________________________________________________________________________

_________________________________________________________________________________________________________________________________

_________________________________________________________________________________________________________________________________

_________________________________________________________________________________________________________________________________

_________________________________________________________________________________________________________________________________

_________________________________________________________________________________________________________________________________

_________________________________________________________________________________________________________________________________

_________________________________________________________________________________________________________________________________

_________________________________________________________________________________________________________________________________

_________________________________________________________________________________________________________________________________

_________________________________________________________________________________________________________________________________

_________________________________________________________________________________________________________________________________

_________________________________________________________________________________________________________________________________

_________________________________________________________________________________________________________________________________

_________________________________________________________________________________________________________________________________

www.TIDESEuropeEvent.com

10-13th November Austria Center | Vienna, Austria

TIDES Europe:Oligonucleotide & Peptide Therapeutics

SEE YOU NEXT YEAR

EVENT GUIDEdownload.knect365lifesciences.com/2019/TidesEuropeGuide.pdf · Don’t forget to pick up...

Documents

Transcript of EVENT GUIDEdownload.knect365lifesciences.com/2019/TidesEuropeGuide.pdf · Don’t forget to pick up...